Preferred Label : alirocumab;

MeSH note : antibody to PCSK9 to manage LDL cholesterol;

CISMeF synonym : SAR236553;

MeSH hyponym : SAR-236553; monoclonal antibody REGN727; REGN727 monoclonal antibody; REGN727;

Is substance : O;

UNII : PP0SHH6V16;

Details


Main resources

You can consult :


https://www.has-sante.fr/jcms/p_3313574/fr/praluent-alirocumab
2022
false
false
false
France
antibodies, monoclonal
antibodies, monoclonal, humanized
insurance, health, reimbursement
hydroxymethylglutaryl-coa reductase inhibitors
Ezetimibe
adult
Heterozygous familial hypercholesterolemia
Atherosclerotic cardiovascular disease
evaluation of the transparency committee
alirocumab

---
https://www.has-sante.fr/jcms/p_3238105/fr/praluent
2021
false
false
false
France
French
evaluation of the transparency committee
treatment outcome
insurance, health, reimbursement
alirocumab
mixed dyslipidemia
hypercholesterolemia
alirocumab
dyslipidemias
Atherosclerotic Cardiovascular Disease
Primary hypercholesterolemia (disorder)
injections, subcutaneous
antibodies, monoclonal

---
https://www.has-sante.fr/jcms/p_3081881/fr/praluent
https://www.has-sante.fr/jcms/pprd_2983646/fr/praluent
2019
false
false
false
France
French
evaluation of the transparency committee
drug therapy, combination
hypercholesterolemia
Atherosclerotic Cardiovascular Disease
adult
cardiovascular diseases
alirocumab
acute coronary syndrome
treatment outcome
insurance, health, reimbursement
alirocumab
antibodies, monoclonal

---
http://www.has-sante.fr/portail/jcms/c_2757882/fr/praluent
2017
false
false
false
false
France
French
treatment outcome
drug approval
alirocumab
hypercholesterolemia
dyslipidemias
adult
injections, subcutaneous
PCSK9 protein, human
insurance, health, reimbursement
evaluation of the transparency committee
alirocumab
Familial hypercholesterolemia - heterozygous (disorder)
Low density lipoprotein apheresis (procedure)
drug therapy, combination
hydroxymethylglutaryl-coa reductase inhibitors
antibodies, monoclonal
serine endopeptidases
proprotein convertases

---
http://www.prescrire.org/Fr/3/31/51924/0/NewsDetails.aspx
2016
false
false
false
France
French
french abstract
evolocumab
hypercholesterolemia
alirocumab
antibodies, monoclonal

---
http://www.has-sante.fr/portail/jcms/c_2629896/fr/praluent
https://www.has-sante.fr/portail/jcms/c_2629896/fr/praluent-alirocumab-hypolipemiant-anti-pcsk9
2016
false
false
false
France
French
treatment outcome
drug approval
alirocumab
hypercholesterolemia
dyslipidemias
adult
injections, subcutaneous
PCSK9 protein, human
Primary hypercholesterolemia (disorder)
insurance, health, reimbursement
evaluation of the transparency committee
alirocumab
guidelines for drug use
mixed dyslipidemia
antibodies, monoclonal
serine endopeptidases
proprotein convertases

---
https://www.ema.europa.eu/medicines/human/EPAR/Praluent
2015
false
false
false
United Kingdom
French
English
treatment outcome
syndication feed
summary of product characteristics
package leaflet
drug evaluation
drug approval
europe
alirocumab
alirocumab
hypercholesterolemia
dyslipidemias
adult
injections, subcutaneous
PCSK9 protein, human
Primary hypercholesterolemia (disorder)
alirocumab
mixed dyslipidemia
antibodies, monoclonal
antibodies, monoclonal
serine endopeptidases
proprotein convertases

---
Nous contacter.
07/06/2024


[Home] [Top]

© Rouen University Hospital. Any partial or total use of this material must mention the source.